JNK inhibitors

Details JNK inhibitors JNK inhibitors

2004-05-14

2009-11-03

Seaman, D. Margaret (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S113000

Reexamination Certificate

active

07612086

ABSTRACT:
The present invention provides novel compounds of formula (I) and their use in the inhibition of c-Jun N-terminal kinases. The present invention further provides the use of these compounds in medicine, in particular in the prevention and/or treatment of neurodegenerative disorders related to apoptosis and/or inflammation.

REFERENCES:
patent: 4719218 (1988-01-01), Bender et al.
patent: 5439917 (1995-08-01), Briving et al.
patent: 5714495 (1998-02-01), Viaud et al.
patent: 6642375 (2003-11-01), Inomata et al.
patent: 7291630 (2007-11-01), Graczyk et al.
patent: 7314940 (2008-01-01), Graczyk et al.
patent: 2002/0013354 (2002-01-01), Cheng et al.
patent: 2005/0272761 (2005-12-01), Graczyk et al.
patent: 2006/0235042 (2006-10-01), Graczyk et al.
patent: 2006/0270646 (2006-11-01), Graczyk et al.
patent: 2007/0072896 (2007-03-01), Khan et al.
patent: 0 509 974 (1992-10-01), None
patent: 0 737 685 (1996-10-01), None
patent: 1 106 621 (2001-06-01), None
patent: 06 247966 (1994-09-01), None
patent: WO-92/10498 (1992-06-01), None
patent: WO-92/10499 (1992-06-01), None
patent: WO-98/47899 (1998-10-01), None
patent: WO-99/20624 (1999-04-01), None
patent: WO-99/21859 (1999-05-01), None
patent: WO-99/51233 (1999-10-01), None
patent: WO-00/26210 (2000-05-01), None
patent: WO-00/26211 (2000-05-01), None
patent: WO-00/35909 (2000-06-01), None
patent: WO-00/35921 (2000-06-01), None
patent: WO-00/43393 (2000-07-01), None
patent: WO-00/56710 (2000-09-01), None
patent: WO-00/64449 (2000-11-01), None
patent: WO-00/64872 (2000-11-01), None
patent: WO-01/12609 (2001-02-01), None
patent: WO-01/47922 (2001-07-01), None
patent: WO-01/49288 (2001-07-01), None
patent: WO-02/10137 (2002-02-01), None
patent: WO-02/16359 (2002-02-01), None
patent: WO-02/081475 (2002-10-01), None
patent: WO-03/028724 (2003-04-01), None
patent: WO-03/082868 (2003-10-01), None
patent: WO-03/082869 (2003-10-01), None
patent: WO-2004/016609 (2004-02-01), None
patent: WO-2004/016610 (2004-02-01), None
patent: WO-2004/078756 (2004-09-01), None
Kontoyiannis et al., Immunity, (Mar. 1999) vol. 10, No. 3, pp. 387-398.
Guillard et al., Heterocycles, 60(4), 2003, pp. 865-877.
Leroy et al., Tetrahedron: Asymmetry (1997), 8(19), 3309-3318.
U.S. Appl. No. 10/591,551.
U.S. Appl. No. 12/143,231.
Adams et al. , Bioorg. Med. Chem. Lett. 2001, 11, 2867-2870.
Alam et al., Synthesis and SAR of aminopyrimidines as novel c-Jun N-terminal kinase (JNK) inhibitors:, Bioorg Med Chem Lett, vol. 17, pp. 3463-3467, 2007.
Bundgaard, Design of ProDrugs, Elsevier Science Publishers 1985.
Cao et al., “Distinct Requirements for p38α andc-Jun N-terminal Kinase Stress-activated Protein Kinases in Different Forms of Apoptotic Neuronal Death”,The Journal of Biological Chemistry, vol. 279, No. 34, pp. 35903-35913, Aug. 20, 2004.
CAS Accession No. 2001:432896, Registry No. 344454-31-1.
CAS Document No. 135:107148.
CAS document No. 135:43132.
Corey, E.Jr., et. al.., A synthetic Method for Formyl-Ethynyl Conversion (RCHO-RC=CH or RC=CR′), Tetrahedron Letters No. 36, Aug. 1972.
Database Beilstein, Beilstein Institute for Organic Chemistry, Citation No. 5563002 (1987).
Denmark et al., “Convergence of Mechanistic Pathways in the Palladium(0)-Catalyzed Cross-Coupling of Alkenylsilacyclobutanes and Alkenylsilanols”Organic Letters. vol. 2, No. 16, pp. 2491-2494. (2000).
Denmark et al., “Highly Stereospecific, Palladium-Catalyzed Cross-Coupling of Alkenylsilanols”Organic Lettersvol. 2, No. 4, pp. 565-568 (2000).
Dhar, et al., “The TosMIC Approach to 3-(Oxazol-5-yl) Indoles: Application to the Synthesis of Indole-Based IMPDH Inhibitors,” Bioorganic & Medicinal Chemistry Letters, 2002.
Eilers et al., “Direct Inhibition ofc-Jun N-terminal Kinase in Sympathetic Neurones Preventsc-junPromoter Activation and NGF Withdrawal-induced Death”,Journal of Neurochemistry. vol. 76, pp. 1439-1454, 2001.
Eilers et al., “Role of the Jun Kinase Pathway in the Regulation ofc-Jun Expression and Apoptosis in Sympathetic Neurons”,The Journal of Neuroscience. vol. 18, No. 5, pp. 1713-1724, Mar. 1, 1998.
Estus et al., “Aggregated Amyloid-β Protein Induces Cortical Neuronal Apoptosis and Concomitant “Apoptotic” Pattern of Gene Induction”,The Journal of Neuroscience, vol. 17, No. 20, pp. 7736-7745, Oct. 15, 1997.
Golub et al., Science, vol. 286, pp. 531-537, Oct 15, 1999.
Greene, T. and Wuts, P.,Protective Groups in Organic Synthesis3rd Edidtion, Wiley, New York (1999).
Guillard, et al. “Synthesis of New Maltonin Analogues from Dimers of Azaindole and Indole by Use of Suzuki Monocoupling”, Heterocycles, vol. 60, No. 4, pp. 865-877 (2003).
Ham et al., “Ac-Jun Dominant Negative Mutant Protects Sympathetic Neurons against Programmed Cell Death”,Neuron, vol. 14, pp. 927-939, May 1995.
Harper and LoGasso,Drugs of the Future2001, 26, 957-973.
Harper et al., “Inhibitors of the JNK Signaling Pathway”,Drugs of the Future, vol. 26, No. 10, pp. 957-973, 2001.
Hatanaka et al., “Cross-Coupling of Organosilanes with Organic Halides Mediated by Palladium Catalyst and Tris(diethylamino)sulfonium Difluorotrimethylsilicate”J. Org. Chem53 pp. 918-920 (1988).
Hatanaka et al., “Highly Selective Cross-Coupling Reactions of Organosilicon Compounds Mediated by Fluoride Ion and a Palladium Catalyst”,Synlettpp. 845-853 (1991).
Henry et al , Bioorg. Med. Chem. Lett. 1998, 8, 3335-3340.
Houwing, et al., Preparation of N-Tosylmethylimino Compounds and their Use in the Synthesis of Oxazoles, Imidazoles and Pyrroles, Tetrahedron Letters No. 2, 1976.
International Search Report for PCT/GB2004/002099, mailed Dec. 2, 2004, 4 pages.
International Search Report for PCT/GB2005/000779, mailed Aug. 12, 2005, 4 pages.
Krasnokutskaya et al.,Khim Geterotsikl. SoedNo. 3 pp. 380-384 (1977).
Kruber, Caplus, Copyright 2007 ACS on STN, 2 pages.
Kumar et al, “Synthesis of 7-Azaindole and 7-Azaoxindole Derivatives through a Palladium-Catalyzed Cross Coupling Reaction”, J. Org. Chem, 57, pp. 6995-6998 (1992).
Lecointe, Reach-trhough Claims, International Pharmaceutical (2002)(also available at <http:///www.bakerbotts.com/infocenter/publications/detail.aspx?id=bffe4a7d-5beb-4cf8-a189-15a190f0eb>).
Lisnock et al., “Activation of JNK3α1 Requires Both MKK4 and MKK7: Kinetic Characterization of in Vitro Phosphorylated JNK3α1”,Biochemistry, vol. 39, pp. 3141-3149, 2000.
Littke et al., “Pd/P(t-Bu)3: A Mild and General Catalyst for Stille Reactions of Aryl Chlorides and Aryl Bromides”J. Am. Chem. Soc. 124 pp. 6343-6348 (2002).
Littke et al., “Versatile Catalysts for the Suzuki Cross-Coupling of Arylboronic Acids with Aryl and Vinyl Halides and Triflates under Mild Conditions”J. Am. Chem. Soc. 122 pp. 4020-4028 (2000).
Martin et al., “Palladium-Catalyzed Cross-Coupling Reactions of Organoboronic Acids with Organic Electrophiles”Acta Chemica Scandinavica47, pp. 221-230 (1993).
Merour et al., Synthesis and Reactivity of 7-Azaindoles (1H-Pyrrolo[2,3-b]pyridine)Current Organic Chemistry5 pp. 471-506 (2001).
Mettey, et al., “Aloisines, a New Family of CDK/GSK-3 Inhibitors. SAR STudy, Crystal Structure in Complex with CDK2, Enzyme Selectivity and Cellular Effects”, J. Med. Chem, 46, pp. 222-236 (2003).
Mitchell, T. “Palladium-Catalysed Reactions of Organotin Compounds”Synthesispp. 803-815 (1992).
Park et al, “A FAcile Synthesis of 2,3-Disubstitute Pyrrolo[2,3-b]pyridines via Palladium-Catalyzed Heteroannulation with Internal Alkynes”, Tetrahedron Letters 39, pp. 627-630 (1998).
Pisano et al, “Bis-indols: a Novel Class of Molecules Enhancing the Cytodifferentiating Properties of Retinoids in Myeloid Leukemia Cells”, Blood, vol. 100, No. 10, pp. 3719-3730 (2002).
Resnick, et al. “Targeting JNK3 for the Treatment of Meurodegenerative Disorders”, Drug Discovery Today, Elsevier Science Ltd. 9:21 (2004) pp. 932

Affiliated with

Also associated with

Rating

JNK inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with JNK inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and JNK inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4095875